Lonza to expand manufacturing drug substance for COVID-19 Vaccine Moderna
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
7.94 crore doses were made available to the states in May 2021
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
This marks Glenmark's first synthetic decapeptide injectable approval
Subscribe To Our Newsletter & Stay Updated